Stay updated on CIMAvax, Nivolumab & Pembrolizumab in Advanced Cancer Clinical Trial
Sign up to get notified when there's something new on the CIMAvax, Nivolumab & Pembrolizumab in Advanced Cancer Clinical Trial page.

Latest updates to the CIMAvax, Nivolumab & Pembrolizumab in Advanced Cancer Clinical Trial page
- Check3 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference0.8%
- Check10 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check46 days agoChange DetectedThe webpage has undergone significant updates, including the removal of detailed information about a clinical trial involving CIMAvax and nivolumab for treating advanced lung and head and neck cancers, while adding new cancer types and registry identifiers.SummaryDifference54%
- Check54 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to February 28, 2025.SummaryDifference0.2%
- Check61 days agoChange DetectedThe page has been updated to reflect a new version release, moving from v2.14.2 to v2.14.3, and the last update date has changed from February 28, 2025, to March 25, 2025.SummaryDifference0.2%
- Check90 days agoChange DetectedThe webpage has undergone significant changes, including the removal of multiple principal investigators and their contact information, as well as updates to the last update posted date and interim analysis details.SummaryDifference2%
Stay in the know with updates to CIMAvax, Nivolumab & Pembrolizumab in Advanced Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CIMAvax, Nivolumab & Pembrolizumab in Advanced Cancer Clinical Trial page.